11/5/2026

speaker
Operator
Conference Call Operator

Welcome to Globus Medical's third quarter 2026 earnings call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks. I will now turn the call over to Shavoon Singh, Senior Vice President of Strategy and Investor Relations. Ms. Singh, please go ahead.

speaker
Shavoon Singh
Senior Vice President of Strategy and Investor Relations

Thank you for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, and Kyle Klin, Chief Financial Officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. As a reminder, our discussion may include forward-looking statements, and such statements are subject to risks and uncertainties Thank you. Thank you. Additionally, we will be discussing certain non-GAAP financial measures on this conference call. We believe these non-GAAP financial measures provide additional information pertinent to our business performance. They should not, however, be considered replacements for or should be read together with the most directly comparable GAAP financial measures. Additional information regarding these non-GAAP financial measures as well as reconciliations for such non-GAAP measures are included in the earnings release and are available on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Keith Pfeil, our President and Chief Executive Officer.

speaker
Keith Pfeil
President and Chief Executive Officer

Thanks, Shagan, and good afternoon, everyone. Before I discuss the quarter, I'd like to formally welcome Shagan Singh to Globus as our new Senior Vice President of Strategy and Investor Relations. Shagan brings more than 20 years of healthcare investment research experience with deep expertise in medical technology and the investment landscape. She will lead our investor relations function as we expand engagement with our shareholders. As our business has grown in size and complexity, we've separated investor relations from corporate development so that each has dedicated leadership. Brian Kearns, who has led both functions for the past 12 years, will continue as Senior Vice President of Corporate Development. I want to thank Brian for the work he's done building relationships with many of you on this call. With that, let's turn to our third quarter results and a longer-term outlook. Our third quarter results totaled $763.7 million, declining 0.7% on an as-reported basis and declining 0.5% on a constant currency basis, reflecting the continued impacts of our rightsizing of Nevro, the timing of delayed new product launches within U.S. Spine, and lower contributions from competitive recruiting. Base business revenue, excluding Nevro, was $690 million, growing 3% as-reported, while Nevro was $73.7 million, declining 25.7% compared to the prior year quarter. Non-GAAP EPS was $1.23, growing 4% over the prior year quarter, while free cash flow was a record $225 million, despite a 13% increase in capital expenditures. Lastly, we deployed $143 million to repurchase 1.9 million shares during the quarter, maintaining our commitment to share buybacks as part of our capital allocation strategy. Our U.S. spine business grew 2% over the prior year quarter, coming off of a tough comp with a slowdown attributed to timing delays around new product launches and lower contributions from competitive recruiting. We've experienced timing delays with new product introductions and lingering production issues. However, actions taken over the past few months are beginning to improve this globally, which will favorably impact our growth as we enter 2027. Growth from new products has been lower than expected due to the timing of key launches. We expect these launches to drive meaningful growth as we enter 2027. On the competitive recruiting front, we need to continually increase the pace of our territory expansions and are taking steps to onboard competitive reps as well as hiring, training, and developing new territories. Looking ahead over the longer term, we remain confident in our ability to grow our U.S. Spine business above market, centered around meaningful new product launches, pull-through growth from capital attachments, and competitive recruiting. Organic innovation still matters and becomes more powerful when you pair that with a strong core spine business, differentiated enabling technologies, and the ability to scale. We possess those core traits and will use them as an advantage as we attack the market and specifically target growth opportunities based on potential market disruptions and dislocations. Now, turning attention to key spine product launches, Our Scrip line of patient-specific implants and rods represents a major launch for Globus into the fast-growing patient-specific implant category. Scrip is comprised of seven new 3D printed inner body cages and new patient-specific rods. Unlike competitive offerings in this space, Scrip will expand expandable and inner fixated cage options in addition to static offerings across ALIF, XLIF, and TLIF categories. Each personalized implant is designed virtually using the new Globus Script Studio software application, allowing surgeons to customize each implant to patient specifications. Combining Script with our full line of implant offerings and market-leading Excelsius technologies positions us as a differentiator in this space, given our full complement of product offerings. Our new X-Lift prone lateral solution showcases our continued ability to innovate in a category we pioneered and we'll continue our technology leadership in the space as it features a newly enhanced patient positioner and the Maxis Air two-blade retractor. The overall solution brings together patient positioning, lateral access and enabling technologies in a manner that is designed to support a connected workflow for prone lateral procedures. These new solutions combine adaptable patient positioning with stable, controlled lateral access to establish a reproducible workflow for prone lateral procedures. The X-Lift Prone Patient Positioner allows adjustments in both the sagittal and coronal planes, while the Maxxis Air Retractor provides a lightweight, rigid platform designed to support soft tissue management and stable access to the disc space. The script line of implants and rods are currently available, while the X-Lift Prone Solution and Two-Blade Retractor will be available later this quarter. Additionally, we are in the final stages of introducing a revolutionary product suite called EIQ. which includes a next-generation pedicle fixation product comprised of implants, instruments, AI-based software planning and execution tools, an intraoperative rod bending machine, and integrated neuromonitoring, all working seamlessly with our eGPS robot, eHub navigation, and e3D imaging systems. We are excited about these products and expect them to be meaningful contributors to revenue in 2027 and beyond. Our Enabling Technologies business delivered $34.9 million to the third quarter, growing 24% driven by increased upfront sales of robots, as well as a continued increase in service revenue. In addition to the increase in upfront revenue, our overall eGPS and eHub units deployed, whether sold, leased, or rented, grew 73% versus the prior year quarter. Looking at the comparable year-to-date figure, our overall eGPS and eHub units deployed are 65% higher versus the prior year to date, demonstrating early results of our approach to increased flexibility and how capital is acquired. During the third quarter, the FDA notified us of the closure of the July 2024 EGPS Warning Letter as a result of the corrective action steps taken. As a reminder, the Warning Letter was focused on administrative tracking of complaint handling and was not an issue of patient safety. Appropriate notifications were shared with both our Salesforce and customers regarding the letters closure. We remain positive on the benefits of our eGPS technology with over 145,000 robotic cases performed to date and see this and navigation with our eHub as key drivers to implant revenue growth in 2027 and beyond. Our Q3 trauma business grew 19% as compared to the prior year quarter. Reflecting on our trauma performance the past few years, the business has remained on a steady growth trajectory. We see surgeons, health systems, reps, and competition beginning to look at Globus trauma differently. In the past, Globus was known as a spine company dabbling in the trauma space. That narrative has shifted where we are now being viewed as a company that is committed to the space and investing in it. Our growth strategy remains focused on converting surgeon teams within level one and level two trauma centers such that we achieve set utilization driving long-term profitable growth. As we look ahead to 2027 and beyond, We expect our trauma business to contribute incrementally higher each year to our consolidated growth going forward. Q3 NEVRO revenue totaled $73.7 million, declining 26% as compared to the prior year quarter given the earlier declines in U.S. trial volumes. Despite the revenue declines, NEVRO adjusted EBITDA margins expanded 370 basis points driven by gross margin expansion and a more disciplined approach to OPEC spending. As we work to recoup lost revenue, we are fully confident that we've right-sized the business, which can now operate in a sustainable manner. We substantially completed the rehiring of sales headcount lost earlier in the year and are starting to see increased output from new associates trained. As we look ahead, we remain focused on stabilizing and getting this business back to a path of growth. The revenue recovery will be driven by increasing the execution of our sales force and growing it through competitive recruiting. In addition, we seek to bring new products to market and I'm excited to share that we will be introducing a new IPG in 2027 named HFX Elite, which is the first innovation to the market since the acquisition of Nevro. HFX Elite will introduce bolus therapy and expanded MRI labeling, allowing more patients access to MRI. HFX Elite is slated for a first half 2027 commercial launch, which we see as a catalyst to drive revenue growth in the new year as we remain committed to the pain market. While Nevro introduced a new continuum of care to Globus with the introduction of pain to our spine franchise, I want to remind everyone that an entry point into pain and SCS were not the only reasons to acquire Nevro. For an acquisition price of $250 million, we've added a technology tuck-in to our portfolio and continue to see uses of the Nevro technology beyond what it is today which we see as drivers to expand the technologies and product development into new areas including cranial, next gen spinal implants, as well as peripheral nerve stimulation. Transitioning this business to a sustainable model of profitability was critical as we investigate the technologies for alternative uses while still working to develop and launch new and exciting products within the core pain franchise. Now that I've covered the quarter pertaining to our business performance, I'd like to step back and spend a few minutes on who we are, where we are going and why we are making those decisions along the way as it will help evaluate us over the next several years. First, our strategy and focus are to develop technologies and procedural solutions that span the continuum of care in the categories in which we operate. We want to innovate, disrupt, and develop a moat that advances patient care while driving operational excellence. Our innovation, whether organic or inorganic, is to develop or enhance a market-leading position that directly ties back to the mission of developing products that promote healing in patients. We are focused on providing our surgeon and hospital partners with a suite of products that are differentiated and meaningful for better clinical outcomes and ease of use by the surgeon. Second, in order to achieve that market leading position, we seek to build dedicated sales teams that will bring deep knowledge and training as well as possessing deep surgeon and hospital relationships that enable us to penetrate markets and be a valuable partner in the operating room. Our success to date in spine and trauma are based on our vast experience in building those dedicated and focused sales teams. Third is our approach to business development. As we look at opportunities, we evaluate based on consistent criteria. Does it strengthen our platform? Does it enhance a current call point? Or will it introduce us to a new call point while driving a meaningful return on capital and improving our overall market growth rate over the long term? Looking ahead, We're going to continue with that formula as we remain active on the business development front. During the third quarter, we completed two small acquisitions with the first being Higgs-Boson in late August. This deal was about driving digital innovation with the mission of transforming the healthcare experience to better shape the patient and provider experience throughout the full episode of care. This deal centered on our goal of improving patient outcomes from the current 70% after 10 years to 95%. Our vision brings the Higgs boson technology into our AI-based surgical intelligence layer by becoming the conduit of data and analytics paired with our class leading implants, technologies, and procedural solutions. The goal is positioning the surgeon to become the best version of themselves using the proper techniques and approaches for their patients through an improved process of matching the right patient with the right implants, procedures, and technologies. Our closed loop will bring that together and monitor outcomes post-op to foster the environment of continuous learning. That vision checks the box that I've described earlier. The second deal closed during the quarter was the acquisition of the Synaptive Assets. This deal was closed through a Canadian receivership bid process and represents a strategic opportunity for Globus to expand into the cranial neurosurgery market, a faster growing market as compared to the current markets in which we operate. We estimate approximately 2 million cranial procedures being performed annually and the acquisition of Synaptiv helps to establish Globus as a leading cranial technology company through the development of an integrated portfolio of enabling technologies and procedural solutions. Built around Excelsior's cranial solutions, MODIS Plan, MODIS-X, clinical services, and future cranial technologies using IP previously acquired or through new IP being developed, The strategy creates a unified ecosystem supporting the full spectrum of neurosurgical procedures. This will focus our cranial investments with the establishment of a dedicated sales team that supports capital equipment with recurring revenue from software, service, clinical support, disposables, as well as instruments and future implant offerings. This roadmap extends beyond the platform navigation into a fully connected ecosystem. Our strategy doesn't move from quarter to quarter. along the way there will be bumps and air pockets, but we maintain focus on the long game to live our mission of improving patients' lives. We remain steadfast on launching new products, meaningfully growing our sales force, and stabilizing Nevro as we look forward to the future. I will now turn the call over to Kyle for additional insights into the quarter and our outlook for the remainder of the year.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API